Mode
Text Size
Log in / Sign up

Case report review of VMAT, utidelone, and denosumab in a breast cancer patient with clivus metastasisRare Breast Cancer Skull Case Achieves Long-Term Remission With New Plan

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider this case report as a reference for rare metastatic breast cancer management.

This publication is a case report review focusing on a single patient with breast cancer and clivus metastasis. The treatment strategy involved volumetric modulated arc therapy (VMAT) combined with concurrent chemotherapy containing utidelone, followed by long-term maintenance of denosumab. The review highlights the specific clinical course of this individual case within the context of limited standardized protocols for such rare presentations.

The primary outcome reported was no recurrence observed during the 30-month follow-up period. No adverse events, serious adverse events, discontinuations, or tolerability data were reported for this patient. The authors emphasize that the lack of unified treatment standards remains a significant challenge in managing these complex metastatic scenarios.

The review acknowledges that early symptoms are often insidious, making detection during routine examinations challenging. Additionally, the authors point out that some patients may develop drug resistance after multiline treatment. Consequently, this evidence is considered preliminary and serves primarily as a reference for the treatment of similar rare metastatic cases rather than establishing broad clinical guidelines.

Imagine finding out cancer has moved to a place doctors rarely check. It is scary to hear about a tumor growing near the base of your skull. This spot is called the clivus. It sits deep inside the head.

Many women worry about where their cancer might go. Usually, it travels to the lungs or bones. But the clivus is a very rare place for it to hide. It is hard to see on standard scans. Doctors might miss it during routine checks.

Why This Skull Spot Is So Tricky

Breast cancer often spreads to lungs or bones. But the clivus is a tricky spot. It is hard to see on standard scans. Doctors might miss it during routine checks.

When it does appear, survival is usually short. Past reports say patients live about nine months. Finding a way to stop it is hard. Many drugs stop working after a while.

Patients often feel frustrated by the lack of options. They want to know if there is a better path. The uncertainty can feel overwhelming for families. They need clear answers about what comes next.

A New Mix Of Drugs And Rays

Doctors used to struggle here. Now a new mix of drugs works. They combined radiation with two different medicines. One drug stops the cancer cells from dividing. The other protects the bone.

Think of the cancer cells like a factory. The first drug turns off the machines. The radiation acts like a targeted strike on the building. The second medicine keeps the foundation strong.

The radiation method is called VMAT. It aims high energy beams at the tumor. It avoids hurting nearby healthy brain tissue. This precision is key for skull cases.

This does not mean this treatment is available everywhere yet.

One Patient Lives Two Years Without Cancer

A recent report shares one patient story. She had breast cancer that moved to her skull. The team used a special radiation method called VMAT. They also gave her the new drug utidelone.

After the main treatment, she took another drug called denosumab. This helped keep her bones healthy. It also helped control the cancer environment.

For thirty months, no cancer came back. This is much longer than the usual nine months. It shows a real chance for recovery.

The patient stayed on the maintenance drug for a long time. This kept the cancer from waking up again. It proves that long-term care matters.

But The Results Are Not Guaranteed

This is just one person's story. It is not a big trial with hundreds of people. We do not know if it works for everyone. Some patients might not respond the same way.

The treatment is complex and expensive. It requires careful monitoring by specialists. Not every hospital has the same equipment. Doctors need to weigh the risks carefully.

Some people might not be able to take the drugs. Side effects can be tough to handle. The body reacts differently to each medicine.

What Happens Next For Patients

Researchers want to test this plan more. They hope to run larger studies soon. This could help create new rules for care.

If more people do well, doctors might use this more often. But approval takes time. Science moves slowly to keep patients safe.

Clinical trials take years to finish. Patients must wait for official guidelines to change. Until then, this case stands as a guide.

For now, this case offers hope. It shows that rare problems can have new solutions. Patients should talk to their doctors about options. Always ask if new treatments fit your situation.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
Breast cancer stands as the most prevalent malignant tumor among women globally and is a significant contributor to cancer-related mortality. The distant metastasis sites of breast cancer patients were mainly the lung, liver and bone. Clivus metastasis of breast cancer is extremely rare and has been reported only in case reports. The early symptoms associated with this type of metastasis are insidious, making detection during routine examination challenging for patients with breast cancer. Previous reports indicate that the median survival for patients with clivus metastasis was only 9.4 months, and there is a lack of unified treatment standards. Some patients develop drug resistance after multiline treatment, presenting significant therapeutic challenges. In this case report, for the rare refractory disease of breast cancer with clivus metastasis, the whole course treatment mode of volumetric modulated arc therapy (VMAT) combined with concurrent chemotherapy with utidelone, followed by long-term maintenance of denosumab, was adopted. Over a follow-up period of 30 months, no recurrence was observed. This regimen combines local lesion control with high-dose radiotherapy and systemic chemotherapy with a novel epirubicin microtubule stabilizer, utidelone. Denosumab, which is used for maintenance therapy after concurrent chemoradiotherapy, is valuable for both bone protection and tumor microenvironment regulation and ultimately achieves rapid and durable clinical remission. This report provides a reference for the treatment of similar rare metastatic cases and provides important preliminary evidence for follow-up clinical research.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.